# Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma

> **NCT02613598** · PHASE1 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 15 (actual)

## Conditions studied

- Hodgkin's Lymphoma
- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT02613598
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-12
- **Primary completion:** 2021-06-07
- **Final completion:** 2021-06-07
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2021-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02613598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02613598, "Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02613598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*